{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:13:47Z","timestamp":1784139227662,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.pan.2025.03.004","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T19:48:09Z","timestamp":1742068089000},"page":"417-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neutrophil-to-apolipoprotein A1 ratio predicted the efficiency of chemotherapy in advanced pancreatic cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"Sen","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yize","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-0640","authenticated-orcid":false,"given":"Qiuxia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2025.03.004_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pan.2025.03.004_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju413","article-title":"Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase iii trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pan.2025.03.004_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Folfirinox versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pan.2025.03.004_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-015-2928-z","article-title":"Phase i study assessing the feasibility of the triple combination chemotherapy of soxiri (s-1\/oxaliplatin\/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma","volume":"77","author":"Yanagimoto","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pan.2025.03.004_bib5","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1158\/1078-0432.CCR-22-2576","article-title":"Hent1 expression predicts response to gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma","volume":"28","author":"Perera","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2025.03.004_bib6","doi-asserted-by":"crossref","first-page":"20963","DOI":"10.1074\/jbc.272.34.20963","article-title":"Low density lipoprotein oxidation and its pathobiological significance","volume":"272","author":"Steinberg","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pan.2025.03.004_bib7","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1038\/s41598-017-05415-9","article-title":"Decreased serum apolipoprotein a1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer","volume":"7","author":"Sirnio","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.pan.2025.03.004_bib8","doi-asserted-by":"crossref","first-page":"18246","DOI":"10.1002\/jcb.29131","article-title":"Diagnostic and prognostic significance of mrna expressions of apolipoprotein a and c family genes in hepatitis b virus-related hepatocellular carcinoma","volume":"120","author":"Wang","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pan.2025.03.004_bib9","doi-asserted-by":"crossref","first-page":"e1434","DOI":"10.1002\/onco.13743","article-title":"Neutrophil-to-apolipoprotein a1 ratio predicted overall survival in hepatocellular carcinoma receiving transarterial chemoembolization","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.pan.2025.03.004_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12032-014-0080-y","article-title":"Elevated apolipoprotein a-i levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma","volume":"31","author":"Jiang","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.pan.2025.03.004_bib11","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.119.039476","article-title":"Apolipoprotein ai) promotes atherosclerosis regression in diabetic mice by suppressing myelopoiesis and plaque inflammation","volume":"140","author":"Barrett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.pan.2025.03.004_bib12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78921","article-title":"Neutrophil-mediated fibroblast-tumor cell il-6\/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: a hybrid clinical-preclinical study","volume":"11","author":"de Castro Silva","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.pan.2025.03.004_bib13","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/lio2.660","article-title":"Neutrophil to apolipoprotein a-i ratio as an independent indicator of locally advanced nasopharyngeal carcinoma","volume":"6","author":"Li","year":"2021","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.pan.2025.03.004_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pan.2025.03.004_bib15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mds494","article-title":"A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an sgctg (scotroc 4) and anzgog study on behalf of gcig","volume":"24","author":"Banerjee","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2025.03.004_bib16","doi-asserted-by":"crossref","first-page":"65982","DOI":"10.18632\/oncotarget.11786","article-title":"Pancreatic stellate cell secreted il-6 stimulates stat3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells","volume":"7","author":"Nagathihalli","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pan.2025.03.004_bib17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pan.2025.03.004_bib18","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1158\/1535-7163.MCT-21-0083","article-title":"Targeting tumor-stromal il6\/stat3 signaling through il1 receptor inhibition in pancreatic cancer","volume":"20","author":"Dosch","year":"2021","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.pan.2025.03.004_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12885-021-09101-y","article-title":"Serum apolipoprotein b to apolipoprotein a-i ratio is an independent predictor of liver metastasis from locally advanced rectal cancer in patients receiving neoadjuvant chemoradiotherapy plus surgery","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2025.03.004_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fphar.2015.00265","article-title":"Apolipoprotein a-i and cancer","volume":"6","author":"Zamanian-Daryoush","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pan.2025.03.004_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.tranon.2017.01.006","article-title":"Impact of serum apolipoprotein a-i on prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer: a propensity score-matched analysis","volume":"10","author":"Quan","year":"2017","journal-title":"Transl Oncol"},{"key":"10.1016\/j.pan.2025.03.004_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12032-014-0407-8","article-title":"Correlation of apolipoprotein a-i kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer","volume":"32","author":"Cheng","year":"2015","journal-title":"Med Oncol"},{"key":"10.1016\/j.pan.2025.03.004_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003147","article-title":"The effect of preoperative apolipoprotein a-i on the prognosis of surgical renal cell carcinoma: a retrospective large sample study","volume":"95","author":"Guo","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.pan.2025.03.004_bib24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s12885-016-2502-z","article-title":"High level of serum apolipoprotein a-i is a favorable prognostic factor for overall survival in esophageal squamous cell carcinoma","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pan.2025.03.004_bib25","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/ATVBAHA.111.226258","article-title":"Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein a-i in in vitro and in vivo models of inflammation","volume":"31","author":"Murphy","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pan.2025.03.004_bib26","series-title":"Hent1 expression predicts response to gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma (pdac)","author":"Perera","year":"2022"},{"key":"10.1016\/j.pan.2025.03.004_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/1078-0432.CCR-17-2180","article-title":"Pancreatic ductal adenocarcinoma subtyping using the biomarkers hepatocyte nuclear factor-1a and cytokeratin-81 correlates with outcome and treatment response","volume":"24","author":"Muckenhuber","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2025.03.004_bib28","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase iii study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pan.2025.03.004_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231186029","article-title":"Efficacy and safety of soxiri versus mfolfirinox in advanced pancreatic cancer","volume":"15","author":"Li","year":"2023","journal-title":"Ther Adv Med Oncol"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390325000572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390325000572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T16:20:14Z","timestamp":1748881214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390325000572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1424390325000572"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2025.03.004","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutrophil-to-apolipoprotein A1 ratio predicted the efficiency of chemotherapy in advanced pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2025.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 IAP and EPC. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}